for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Microbix Biosystems Inc

MBX.TO

Latest Trade

0.61CAD

Change

-0.02(-3.17%)

Volume

71,077

Today's Range

0.60

 - 

0.63

52 Week Range

0.22

 - 

0.72

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
0.63
Open
0.63
Volume
71,077
3M AVG Volume
2.67
Today's High
0.63
Today's Low
0.60
52 Week High
0.72
52 Week Low
0.22
Shares Out (MIL)
123.90
Market Cap (MIL)
75.58
Forward P/E
20.33
Dividend (Yield %)
--

Latest Developments

More

Microbix Posts Q2 Revenue Of C$4.354 Million

Microbix Receives $4.25 Million Order For Viral Transport Medium

Microbix Reports Results For Fiscal 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Microbix Biosystems Inc

Microbix Biosystems Inc is a Canada-based life science company and manufacturer of viral and bacterial antigens and cell, culture-based biological products and technologies. The Company has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The Company's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.

Industry

Biotechnology & Drugs

Contact Info

265 Watline Avenue

MISSISSAUGA, ON

L4Z 1P3

Canada

+1.905.3618910

https://microbix.com/

Executive Leadership

Martin A. Marino

Independent Chairman of the Board

Cameron L. Groome

President, Chief Executive Officer, Director

James S. Currie

Chief Financial Officer

Philip J. Casselli

Senior Vice President - Sales and Business Development

Mark Luscher

Senior Vice President - Scientific Affairs

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2020

0.0K

2021(E)

0.0K
EPS (CAD)

2020

-0.060

2021(E)

0.030
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.76
Price To Book (MRQ)
8.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
77.07
LT Debt To Equity (MRQ)
60.88
Return on Investment (TTM)
-29.81
Return on Equity (TTM)
-23.21

Latest News

Latest News

BRIEF-Microbix Covid-19 QAPS Attain EU 'CE Mark' Registration

* MICROBIX BIOSYSTEMS - ATTAINED CE MARKING IN COMPLIANCE WITH EUROPEAN IN-VITRO DIAGNOSTIC DEVICES DIRECTIVE

BRIEF-Microbix Reports Quality Products Distribution Agreement

* MICROBIX BIOSYSTEMS INC - APPOINTMENT OF ALPHA-TEC SYSTEMS AS DISTRIBUTOR OF ITS QUALITY ASSESSMENT PRODUCTS FOR U.S. Source text for Eikon: Further company coverage:

BRIEF-Microbix Biosystems Inc - Achieved Full Utilization Of Six Bioreactor Units

* MICROBIX BIOSYSTEMS INC - ACHIEVED FULL UTILIZATION OF SIX BIOREACTOR UNITS Source text for Eikon: Further company coverage:

BRIEF-Microbix Announces Quality Products Distribution Agreement

* MICROBIX BIOSYSTEMS - APPOINTMENT OF R-BIOPHARM AG (R-BIOPHARM) AS DISTRIBUTOR OF ITS QUALITY ASSESSMENT PRODUCTS IN 11 COUNTRIES Source text for Eikon: Further company coverage:

BRIEF-Microbix Biosystems Q2 Revenue Falls 32% To C$2.874 Million

* DURING Q2 MICROBIX RAISED $2,150,159 (NET OF ISSUE COSTS) IN A PRIVATE PLACEMENT

BRIEF-Microbix Announces Quality Products Distribution Agreement

* MICROBIX BIOSYSTEMS- APPOINTMENT OF DIAGNOSTIC INTERNATIONAL DISTRIBUTION S.P.A. OF MILAN AS DISTRIBUTOR OF ITS QUALITY ASSESSMENT PRODUCTS FOR ITALY Source text for Eikon: Further company coverage:

BRIEF-Microbix Says COVID-19 QAPs Now Available For U.S. Labs

* MICROBIX COVID-19 QAPS NOW AVAILABLE FOR U.S. LABS Source text for Eikon: Further company coverage:

BRIEF-Microbix Begins Providing COVID-19 Test Quality Products

* MICROBIX BIOSYSTEMS - BEGUN PROVIDING ITS REDXFLOQ SARS-COV-2 SWAB-FORMAT

BRIEF-Microbix Biosystems To Provide A Global External Quality Assessment Program To Support Clinically-Effective Covid-19 Testing

* MICROBIX BIOSYSTEMS INC - TO PROVIDE A GLOBAL EXTERNAL QUALITY ASSESSMENT PROGRAM TO SUPPORT CLINICALLY-EFFECTIVE COVID-19 TESTING Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Microbix Creates Quality Assessment Product For COVID-19 Tests

* MICROBIX CREATES QUALITY ASSESSMENT PRODUCT FOR COVID-19 TESTS Source text for Eikon: Further company coverage:

BRIEF-Microbix Announces Quality Products Distribution Agreement

* MICROBIX BIOSYSTEMS INC - APPOINTMENT OF MEDICAL SUPPLY COMPANY OF IRELAND (MSC) AS A DISTRIBUTOR Source text for Eikon: Further company coverage:

BRIEF-Microbix Reports Q1 Revenue Of C$2.046 Million

* QTRLY NET COMPREHENSIVE LOSS PER SHARE $0.006 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up